靶点- |
|
|
|
|
|
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease
This study will evaluate the safety of an investigational cell transplantation therapy, ISC-hpNSC, in patients with Parkinson's disease. All patients will receive the therapy, which consists of human neural stem cells. Three dose levels will be examined in the study.
100 项与 Cyto Therapeutics Pty Ltd. 相关的临床结果
0 项与 Cyto Therapeutics Pty Ltd. 相关的专利(医药)
100 项与 Cyto Therapeutics Pty Ltd. 相关的药物交易
100 项与 Cyto Therapeutics Pty Ltd. 相关的转化医学